New shuttle session with our in vivo syngeneic tumor models – for cost-saving efficacy studies
07 / 16 / 2019
-
07 2019
Press release & events
05 2019
Explicyte intensifies its efforts in translational research and will be attending the ASCO Annual Meeting 2019 in Chicag
05 / 21 / 2019
By setting new facilities within the cancer center “Institut Bergonié”, Explicyte - in addition to its preclinical research capabilities - strengthens its development towards clinical translational research, to provide new services based on multiparametric experimental biomarker analysis, for target identification and monitoring of the immune response in the context of clinical trials.
04 2019
Orthotopic glioblastoma mouse model in a new shuttle session - Cost-effective & time-saving efficacy studies
04 / 23 / 2019
Our syngeneic glioma mouse model, based on the intracranial inoculation of Luc2-expressing GL261 cells and bioluminescence imaging for tumor growth monitoring, represents a suitable tool for chemo- and immunotherapy assessment. It closely mimics the human disease in terms of tumor progression and anti-tumor response, and recapitulates glioblastoma characteristic features including among others tumor immune cell infiltration and tumor-induced immunosuppression.
03 2019
Explicyte and Institut Bergonié partners for comprehensive translational research programs in immuno-oncology
03 / 25 / 2019
Bordeaux, FRANCE, March 24, 2019: Explicyte and Institut Bergonié, have entered into a collaboration to conjointly drive a translational research program aiming at identifying resistance mechanisms to immune checkpoint inhibitors in cancer patients.
03 2019
Explicyte will be attending the AACR Annual Meeting 2019 in Atlanta
03 / 20 / 2019
We will be attending the AACR Annual Meeting in Atlanta, from March 29 to April 3, 2019. We will be glad to take this opportunity to meet you there, describe our service offerings and approach your research projects.
03 2019
Job offer - Open position / Technical manager
03 / 07 / 2019
Job offer / Offre d’emploi
Technical manager / Technicien de laboratoire
Télécharger l'offre d'emploi
05 2018
Eurostars Granted Project “A Novel Modified Natural Killer (NK) Cell Immunotherapy For The Treatment Of Solid Tumours” –
05 / 17 / 2018
Eurostars, a European joint programme, co-funded from the national budgets of several EUREKA countries and by the European Union through Horizon 2020 has awarded, through a highly-competitive selection process, the Project “A novel modified natural killer (NK) cell immunotherapy for the treatment of solid tumours” – MODIFY-NK.
03 2016
Former Executives Of Fluofarma Joins Explicyte
03 / 15 / 2016
Two former key executives of preclinical CRO Fluofarma will join Explicyte in March 2016. This new brand, powered by ImmuSmol, offers preclinical contract research services in immuno-oncology, and intends to release specialty research services in the field of neurobiology by the end of 2016.